Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07104331 · ClinicalTrials.gov registry record · Phase 2
SARC046: A Phase II Trial of Nab-Sirolimus in Patients With Progressing or Symptomatic Epithelioid Hemangioendothelioma
A Phase 2 study of Epithelioid Hemangioendothelioma (EHE), sponsored by Sarcoma Alliance for Research through Collaboration.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
- 6
- Study locations
NCT07104331 is a Phase 2 study of Epithelioid Hemangioendothelioma (EHE) that is actively recruiting participants, run by Sarcoma Alliance for Research through Collaboration. The registered enrollment target is 41 participants. The trial reports 6 study locations across 5 states.
The verdict
NCT07104331, a Phase 2 study of Epithelioid Hemangioendothelioma (EHE), is actively recruiting participants, sponsored by Sarcoma Alliance for Research through Collaboration.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
- 6
- Study locations
Study Summary
This is a non-randomized, open label, single arm Phase II trial with a two-stage design with histologically-confirmed metastatic and/or recurrent epithelioid hemangioendothelioma requiring systemic treatment. nab-Sirolimus 100 mg/m2 will be administered as an intravenous infusion over 30 minutes on Days 1 and 8 of each 21-day cycle. The primary objective is to determine ORR by RECIST v1.1 of nab-sirolimus in patients with EHE who require systemic treatment.
Conditions Studied
Interventions
- DRUG nab-Sirolimus
Study Locations (6)
Massachusetts
- Brigham and Women's Hospital - Boston
- Dana-Farber Cancer Institute - Boston
California
- Stanford University - Stanford
Colorado
- University of Colorado - Aurora
Missouri
- Washington University St. Louis - St Louis
New York
- Sloan Kettering Institute for Cancer Research - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2026-02-24 |
| Est. Completion | 2029-08-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07104331
The ClinicalTrials.gov registry entry for NCT07104331 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sarcoma Alliance for Research through Collaboration, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Epithelioid Hemangioendothelioma (EHE) appearing as the primary indexed condition, and to 1 intervention - of which nab-Sirolimus is the first listed.
NCT07104331 reports 6 study locations spanning 5 distinct geographic areas - top geographies include Massachusetts, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT07104331 about?
NCT07104331 is a clinical study titled "SARC046: A Phase II Trial of Nab-Sirolimus in Patients With Progressing or Symptomatic Epithelioid Hemangioendothelioma". This is a non-randomized, open label, single arm Phase II trial with a two-stage design with histologically-confirmed metastatic and/or recurrent epithelioid hemangioendothelioma requiring systemic treatment. nab-Sirolimus 100 mg/m2 will be administered as an intravenous infusion over 30 minutes on ...
What is the current status of trial NCT07104331?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2026-02-24. Estimated completion is 2029-08-30.
What conditions does trial NCT07104331 study?
This clinical trial studies the following conditions: Epithelioid Hemangioendothelioma (EHE).
What interventions are being tested in trial NCT07104331?
The interventions under investigation include: nab-Sirolimus (DRUG).
Who is sponsoring clinical trial NCT07104331?
This trial is sponsored by Sarcoma Alliance for Research through Collaboration, which has 20 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07104331 being conducted?
This trial has 6 study locations across California, Colorado, Massachusetts, Missouri, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.